China market dynamics and innovation sourcing
6 statements on the record across 3 companies, ordered by how much each has said. Every quote is verbatim from its call.
Across the sector, China features both as a source of innovation and a driver of demand volatility. BMY's Boerner points to significant innovation activity in China but has not committed to specific sourcing targets or dates [m2300], while PFE's Baum moved from flagging China's cross-therapeutic-area innovation in February 2025 to citing the 3SBio deal as a foundational asset by November 2025, marking a shift from observation to concrete business development [m2241, m2341]. On the demand side, MRK's Litchfield initially attributed a 40% Gardasil decline to elevated channel inventories and soft demand specifically in China [m2183], but later widened the explanation to a 35% drop to $1 billion citing lower demand in both China and Japan [m2183, m2438]. Litchfield also noted that growth outside the US and China was supported by Japan's catch-up cohort, underscoring divergent regional demand patterns [m2184].
Litchfield attributed a 40% Gardasil decline to elevated channel inventories and soft demand in China. [m2183] Litchfield noted growth outside the US and China was driven by demand including Japan's catch-up cohort. [m2184] Litchfield later reported Gardasil sales fell 35% to $1 billion, now citing lower demand in both China and Japan, widening the geographic scope from the earlier China only channel inventory explanation. [m2183, m2438]
Show the 3 verbatim statements
#m2183 · 2025-04-24 · Caroline Litchfield · STATED
“In vaccines, GARDASIL sales were $1.3 billion, a decrease of 40% driven by China where we see elevated channel inventories and continued soft demand.”
#m2184 · 2025-04-24 · Caroline Litchfield · STATED
“In the US, sales benefited from price and demand. Outside the US and China, growth was driven by higher overall demand including from the catch-up cohort in Japan.”
#m2438 · 2026-02-03 · Caroline A. Litchfield · STATED
“In vaccines, Gardasil sales were $1 billion, a decrease of 35% driven by lower demand in China and Japan.”
Baum noted in February 2025 that China's cross-therapeutic-area innovation had drawn Pfizer's attention. [m2241] By November 2025, Baum said Pfizer is very active in China, citing the 3SBio deal as a foundational asset across multiple indications. [m2341] This marks a shift from watching Chinese innovation to concrete business development action in China. [m2241, m2341]
Show the 2 verbatim statements
#m2241 · 2025-02-04 · Andrew Baum · STATED
“On your point regarding China, it has not escaped our attention. Of course, the innovation from China across multiple therapeutic areas.”
#m2341 · 2025-11-04 · Andrew Baum · STATED
“I mean I'd echo what Dave said that we are very active in all geographies, especially in China. You saw the 3SBio, which has a foundational asset to become the backbone across multiple indications.”
Boerner noted significant innovation activity occurring in China, without committing to specific sourcing targets or dates. [m2300]
Show the 1 verbatim statement
#m2300 · 2025-04-24 · Christopher Boerner · STATED
“there's certainly a lot of exciting innovation taking place in China.”
OPEN is an unresolved commitment on the clock; STATED is on the record without a checkable bar and is never counted or scored. Method: methodology.